Precigen, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Helen Sabzevari
- Full Time Employees
- 143
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 20374 Seneca Meadows Parkway Germantown MD United States of America 20876
- IPO Date
- Aug 8, 2013
- CIK
- 0001356090
- Website
- precigen.com
- Similar Companies
- Business
- Precigen, Inc. (Nasdaq: PGEN) is a clinical-stage biopharmaceutical company that develops gene and cell therapies using proprietary precision technologies to target diseases in immuno-oncology, autoimmune disorders, and infectious diseases; its core platforms include the AdenoVerse immunotherapy platform, which employs proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and the UltraCAR-T platform, which provides controllable chimeric antigen receptor T-cell therapies for hematological malignancies and solid tumors. The company offers PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved AdenoVerse gene therapy for recurrent respiratory papillomatosis (RRP) in adults; additional pipeline candidates such as PRGN-2009 in combination with pembrolizumab for HPV-associated cancers, PRGN-3005 for ovarian cancer, PRGN-3006 for acute myeloid leukemia and myelodysplastic syndromes, and PRGN-3007 for hematological and solid tumors; and services through its Exemplar subsidiary, which develops research models for healthcare applications including the UltraPorator electroporation device. Founded in 1998 and headquartered in Germantown, Maryland, Precigen operates primarily in the United States with a focus on advancing therapies from discovery through commercialization. Recent developments include the FDA approval of PAPZIMEOS in 2025, a $125 million non-dilutive credit facility with Pharmakon Advisors in September 2025 featuring a $100 million initial tranche to support U.S. commercialization of PAPZIMEOS and international expansion, and a $79 million private placement of preferred stock in December 2024 extending cash runway into 2026.
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
Precigen: Full Commercial Validation And Room To Run
Precigen Q1 Earnings Call Highlights
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen (NASDAQ:PGEN) Shares Gap Up on Analyst Upgrade
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates